On 21 March 2018, orphan designation (EU/3/18/2006) was granted by the European Commission to Quintiles Ireland Limited, Ireland, for tazemetostat for the treatment of malignant mesothelioma.
In May 2018, Quintiles Ireland Limited changed name to IQVIA RDS Ireland Limited.
|Disease / condition||
Treatment of malignant mesothelioma
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.